Ipilimumab – new option for Metastatic Melanoma patients

Print pagePDF pageEmail page

At ASCO this past weekend, Dr. Steven O’Day reported that ipilimumab alone or in combination with vaccine increased overall survival (OS) in patients with unresectable stage III/IV melanoma for whom previous treatment had failed (Abstract 4). 

Metastatic (stage IV) melanoma is very difficult to treat with no new approved choices since IL-2 over a decade ago. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), is an immune therapy directed against T-cells. Blocking this antigen helps to stimulate the expansion of T-cell populations, potentially increasing tumor-directed immune responses. 

Study design
Two therapeutic approaches — ipilimumab and vaccine therapy with gp100 alone and in combination. 

  • double-blind study randomly assigned patients to receive 1) ipilimumab (137 patients), 2) ipilimumab and gp100 (403 patients), or 3) gp100 alone (136 patients).
  • All patients were required to be HLA-A2 positive.
  • Primary endpoint:  overall survival (OS).

Result
 After 12 months, 46% of patients receiving ipilimumab alone, 44% receiving ipilimumab plus gp100, and 25% receiving gp100 were still alive. (p = 0.0026 for ipilimumab alone versus gp100; p = 0.0004 for the combination versus gp100) [See Fig.1] 

Figure 1

Figure 1 Ipilimumab

 

Adverse events
Adverse events were predominantly immune response–related and included rash, colitis, diarrhea, and hepatitis. More serious immune-related grade 3 or 4 toxicities occurred in 10% to 13% of patients receiving ipilimumab.  Physicians treating melanoma should be familiar with the side effects and its management.  “Even at 3mg/kg, there were potentially life-threatening complications.  Using ipilimumab requires a committed, multidisciplinary team at all times to address toxicity management.” Dr. V. Sondak said. 

Information on clinical trials on ipilimumab 

Visit us at http://healthreason.com for more articles like this.

Print Friendly
Be Sociable, Share!
This entry was posted in Cancer, Melanoma and tagged , , , , . Bookmark the permalink.
0 comments